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Abstract
Autophagy occurs at a basal level in all eukaryotic cells and may support cell survival or activate death pathways. Due
to its pathophysiologic signiﬁcance, the autophagic machinery is a promising target for the development of multiple
approaches for anti-neoplastic agents. We have recently described the cytotoxic and pro-apoptotic mechanisms,
targeting the tumour suppressor p53, of climacostol, a natural product of the ciliated protozoan Climacostomum virens.
We report here on how climacostol regulates autophagy and the involvement of p53-dependent mechanisms. Using
both in vitro and in vivo techniques, we show that climacostol potently and selectively impairs autophagy in multiple
tumour cells that are committed to die by apoptosis. In particular, in B16-F10 mouse melanomas climacostol exerts a
marked and sustained accumulation of autophagosomes as the result of dysfunctional autophagic degradation. We
also provide mechanistic insights showing that climacostol affects autophagosome turnover via p53-AMPK axis,
although the mTOR pathway unrelated to p53 levels plays a role. In particular, climacostol activated p53 inducing the
upregulation of p53 protein levels in the nuclei through effects on p53 stability at translational level, as for instance the
phosphorylation at Ser15 site. Noteworthy, AMPKα activation was the major responsible of climacostol-induced
autophagy disruption in the absence of a key role regulating cell death, thus indicating that climacostol effects on
autophagy and apoptosis are two separate events, which may act independently on life/death decisions of the cell.
Since the activation of p53 system is at the molecular crossroad regulating both the anti-autophagic action of
climacostol and its role in the apoptosis induction, it might be important to explore the dual targeting of autophagy
and apoptosis with agents acting on p53 for the selective killing of tumours. These ﬁndings also suggest the efﬁcacy of
ciliate bioactive molecules to identify novel lead compounds in drug discovery and development.
Introduction
Macroautophagy (hereafter autophagy) targets the
delivery of intracellular content to the lysosomal com-
partments, via the formation of double-membraned
vesicles termed as autophagosomes1–4. Autophagy is
controlled by a set of evolutionarily conserved autophagy-
related proteins5, occurs at a basal level in all eukaryotic
cells, including the unicellular organisms6, and is
modulated by diverse endogenous systems and cellular
stresses7–9. The role of autophagy in cell fate is con-
troversial since it may support cell survival, also via sup-
pression of cell death (including apoptosis, necrosis or
other forms of non-apoptotic cell death), and activate
death pathways10–12. Due to the pathophysiologic sig-
niﬁcance of both malfunction and over-activation of
autophagy in different diseases, such as cardiomyopathies,
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muscular dystrophy, metabolic syndromes, infectious-
immune diseases, and neurodegenerative disorders,
autophagy has been intensively studied in the past dec-
ades7,8,13. Noteworthy, as it links cancerous and non-
transformed components of the tumour microenviron-
ment, autophagy and its network are important for
tumour initiation, progression and response to therapy14.
In particular, efﬁcient autophagic responses in pre-
malignant cells suppress transformation (anti-cancer
function) while autophagy supports the natural progres-
sion of neoplasms (pro-cancer mechanism). This places
the autophagic machinery in the limelight as a promising
target for development of multiple approaches for anti-
neoplastic agents such as promotion of autophagy for the
purpose of cancer prevention and suppression of autop-
hagy as therapeutic intervention in different types of
established cancers, including melanoma12,14,15.
Natural compounds are involved in the modulation of
several cellular events, thus showing a great potential
to unravel physiological process and to be translated
into clinical use, as for instance cancer treatment16,17.
Among the bioactive molecules isolated from aquatic
eukaryotic microorganisms18, we have recently described
the cytotoxic and pro-apoptotic effects of climacostol
[(Z)-5-(non-2-en-1-yl)benzene-1,3-diol], a natural toxin
physiologically produced by the freshwater ciliated pro-
tozoan Climacostomum virens19,20, in tumour cells18,21–24.
Both in vitro and in vivo evidence demonstrated that
climacostol inhibits the viability/proliferation of mouse
melanoma cells, induces a persistent inhibition of tumour
growth and improves the survival of transplanted mice
thus triggering the cell death process as a result of DNA
damage and apoptosis18,23. The signalling events respon-
sible for the climacostol-induced pro-apoptotic effects
rely on the up-regulation of p53 tumour suppressor net-
work that, in turn, activates the intrinsic programmed cell
death pathway.
The transcription factor p53 is one of the major barriers
against cancer25,26. However, the exact mechanisms by
which p53 mediates tumour suppression are not under-
stood. Whereas p53-dependent modulation of apoptosis
appear crucial for p53-mediated tumour suppression
in some studies, in other ones their involvement in
p53 effects may be dispensable27. Experimental evidence
reports that p53, depending on its localisation and mode
of action, can act as either an activator or an inhibitor
of autophagy25,28. Although the extent to which autop-
hagy regulation determines cell death/survival by p53
is unclear, it may underlie key aspects on the biology
and treatments of cancer25,28–31.
A large number of natural products are involved in
autophagy modulation through multiple signalling path-
ways and transcriptional regulators32. In this context,
we investigated here how climacostol regulates autophagy
through both in vitro and in vivo approaches, as well as
the involvement of p53-dependent mechanisms and their
impact on autophagosome turnover and cell fate.
Results
Climacostol disrupts autophagy in mouse melanoma:
in vivo and in vitro evidence
The activity of climacostol in vivo was described in a
melanoma allograft model, the B16-F10 cells injected
subcutaneously in mice18,23. The experimental procedure
consisted of 100 µl intra-tumour injections of climacostol
at 600 μg/ml or vehicle (control) every 3–4 days for ca.
3 weeks. Using the same experimental paradigm, we
deﬁned the autophagy levels in melanomas locally treated
with climacostol at day 16. First, we analysed mRNA
levels of autophagy mediators by real-time PCR in
tumours1–4. Transcripts encoding LC3b, p62, beclin 1,
bnip 3, bnip 3L, atg3, atg4, and atg5 autophagy genes
signiﬁcantly enhanced in climacostol-treated group
(Supplementary Fig. 1a), suggesting a perturbation of
autophagic machinery.
An increase of LC3 staining and the detection of LC3
puncta, reminiscent of autophagosome formation, was
detected in melanoma from climacostol-administered
mice, whereas diffuse LC3 staining was visualised in
control samples (Fig. 1a). Climacostol treatment also
increased lipidated LC3 (LC3-II) levels (Fig. 1b). The
lipidation and clustering of LC3 may be the result of both
induction and suppression of autolysosomal maturation.
The cargo protein p62 is a useful method to distinguish
whether autophagosome accumulation is due to autop-
hagy induction rather than an inhibition3,4. As shown in
Fig. 1c, treatment of B16-F10 allografts with climacostol
signiﬁcantly increased p62 immunoﬂuorescence leading
to accumulation of p62-positive aggregates. These results
were conﬁrmed by western blot experiments detecting an
increase of p62 protein band in climacostol-treated
tumours (Fig. 1d).
B16-F10 cells were treated in vitro with climacostol at its
target dose for potency and efﬁcacy (30 μg/ml), inducing
cytotoxic, anti-proliferative and pro-apoptotic effects18,23.
Similarly to in vivo results, 24 h climacostol treatment
increased immunoﬂuorescence intensity and puncta of
LC3 (Fig. 2a) and LC3 cleavage (Fig. 2b). In addition, we
observed higher levels of aggregated p62 and a signiﬁcant
increase of p62 staining in climacostol-treated cells
(Fig. 2c) which paralleled with an accumulation of p62
immunoblot levels (Fig. 2d). The effect of climacostol on
autophagy was then evaluated by treating cells with the
known autophagic ﬂux inhibitor chloroquine (CQ)8. B16-
F10 cells treated with CQ (10 μM, 6 h)33 showed an
increased amount of lipidated LC3 and accumulation of
p62 (Fig. 3a, b). Of notice, 24 h climacostol-induced
accumulation of LC3-II and p62 was not modiﬁed in the
Zecchini et al. Cell Death and Disease           (2019) 10:10 Page 2 of 19
Ofﬁcial journal of the Cell Death Differentiation Association
Fig. 1 (See legend on next page.)
Zecchini et al. Cell Death and Disease           (2019) 10:10 Page 3 of 19
Ofﬁcial journal of the Cell Death Differentiation Association
presence of CQ. The absence of an additive effect between
CQ and climacostol is consistent with the inhibition of the
autophagic ﬂux exerted by climacostol.
The autophagic response was then analysed using
transmission electron microscopy. As shown in Fig. 3c,
B16-F10 cells treated with climacostol for 6 h showed
accumulation of autophagosomes in the cytosol. Autop-
hagosomes, also referred to as initial autophagic vacuoles
(AVi), have been deﬁned as a double-membraned struc-
ture containing undigested cytoplasmic contents4. The
parallel membrane layers (bilayers) of AVi are separated
by a relatively narrower or wider electron-translucent
cleft, sequestering cytosol, mitochondria, or endoplasmic
reticulum membranes not yet degraded. Differently, late
or degradative autophagic vacuoles (AVd)4, deﬁned as a
hybrid organelle generated by the fusion of an autopha-
gosome and a lysosome were clearly detectable in control
but scarce in climacostol-administered cells (Fig. 3c). The
AVd showed a single membrane and contained materials
at various stages of degradation, visualised as intense, dark
structures within the vacuoles4. Climacostol-treated cells
moreover showed disorganised structures, swollen cristae
in mitochondria and accumulation of melanosomes in
the cytoplasm.
B16-F10 cells were transiently transfected with a red
ﬂuorescent protein (mRFP)-green ﬂuorescent protein
(GFP)-LC3 as a dual-ﬂuorescence pH sensor of autop-
hagic vacuoles in live cells34. The expression of this
reporter results in both green and red ﬂuorescence and
detects autophagosomes (pH neutral) and
autophagosome-lysosome fusion (pH acid)4,34, as autop-
hagosomes appear yellow and autolysosomes as only red
vacuoles, since the low lysosomal pH quenches GFP more
quickly than mRFP. In control conditions, about half of
autophagic vacuoles had only red ﬂuorescence signal
while the other half had yellow signal (Fig. 4a, b). After
treatment of the cells with climacostol, yellow punctate
ﬂuorescence signiﬁcantly increased whilst only-red
puncta markedly decreased, indicating a time-dependent
blockade of autophagosome maturation/autophagosome-
lysosome fusion. The effect of climacostol was detected at
3 h (although below the statistical signiﬁcance) and
reached the almost maximal effect already at 6 h. Close to
90% of the autophagic vacuoles had yellow signals fol-
lowing 24 h treatment. Similar results were observed with
CQ alone (10 μM, 6 h). The kinetics of climacostol was
further conﬁrmed by immunoblot experiments showing
evident LC3 cleavage and p62 accumulation induced by 6
h of treatment (Fig. 4c).
Climacostol induces cell death/apoptosis and impairs
autophagy in human and murine tumour cells
Human melanoma A375 and SK-MEL-5, murine
glioma GL261 and human glioblastoma U87MG cells
were treated for 24 h with climacostol. In agreement
with previous results in multiple human and rodent
cell lines18,21–23, climacostol caused a concentration-
dependent reduction of cell viability with an Emax con-
centration value (nearly 100% inhibition) of ca. 30 μg/ml,
as assessed by the MTT assay (Fig. 5a–d). Data also
indicated that climacostol affects the viability with a
comparable potency among cells, i.e., EC50 of 5.7, 6.4, 6.7
and 5.8 μg/ml for A375, SK-MEL-5, GL261 and U87MG
cells, respectively. Similar results were obtained in B16-
F10 cells as a control (Supplementary Fig. 1b)23. Clima-
costol treatment (24 h, 30 μg/ml) induced apoptosis
and impaired autophagy in A375, SK-MEL-5, GL261 and
U87MG cells since it increased the expression of cleaved-
(active) executioner caspase 3 and led to an accumulation
of LC3-II and p62 (Fig. 5e–h).
Climacostol signalling regulating autophagy: p53-
dependent and independent effects
Climacostol-induced pro-apoptotic effects in melanoma
rely on the up-regulation of p53 that, in turn, activates the
intrinsic programmed cell death pathway, including cas-
pase 318,23. This is conﬁrmed by the analysis of cleaved-
caspase 3 in B16-F10 cell transfected for 48 h with a p53-
speciﬁc or a non-targeting siRNA23, followed by clima-
costol treatment (24 h, 30 μg/ml). Indeed, when the
climacostol-dependent increase of p53 was silenced
(Supplementary Fig. 2a) the activation of caspase 3 was
abolished (Fig. 6a). The mRNA of p53 did not change
(Fig. 6b) while p53 protein clearly enhanced following
climacostol exposure, with a detectable effect obtained at
6 h of treatment (Fig. 6c). Consistently, we detected a
time-dependent accumulation of p53, almost completely
localised in the nuclei of B16-F10 cells (Fig. 6d). The p53
protein phosphorylated at Ser15 site (p-p53Ser15), a
modiﬁcation responsible of p53 stability25,26, up-regulated
(see ﬁgure on previous page)
Fig. 1 Climacostol impairs autophagy in in vivo melanoma. Subcutaneous B16-F10 melanoma allografts were excised from mice at day 16 of
treatment (from day 0 - every 3–4 days) with 100 µl climacostol (CLIMA; 600 μg/ml) or control vehicle (CTRL). a, c Immunoﬂuorescence imaging of
LC3 and p62. DAPI was used for nuclei detection. Scale bar: 50 μm. Inserts represent enlarged image details. Lower panels: quantitative analysis of LC3
and p62 immunoﬂuorescence. A total of 6 different images were analysed per tumour. Results are expressed as fold change of CTRL. b, d Western
blotting images of LC3 and p62 expression. LDH was used as internal standard. Lower panels: densitometric analysis of LC3-II and p62 relative to their
respective standard. Results are expressed as fold change of CTRL. Images and data represent the results obtained from 6 animals per experimental
group. **p < 0.01 and ***p < 0.0001 relative to CTRL
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as well in the presence of climacostol and p53/p-p53Ser15
staining was superimposable, thus indicating a post-
translational effect on p53 induced by climacostol.
We then determined whether the role of climacostol on
autophagic ﬂux involved p53 signalling. The silencing of
p53 perturbed climacostol effects on autophagic ﬂux. LC3
lipidation in response to climacostol (24 h, 30 μg/ml) was
still active (Fig. 6e). By contrast, p62 levels signiﬁcantly
decreased in p53 siRNA cells treated with climacostol
reaching values comparable to control (Fig. 6e), despite
climacostol inducing a sustained increase of the mRNA
encoding p62 in native cells (Supplementary Fig. 2b). This
is consistent with a sustained autophagy turnover induced
by climacostol in the absence of p53, thus suggesting that
climacostol treatment simultaneously induces autopha-
gosome formation and compromises autophagosome
turnover, this latter via the up-regulation/phosphorylation
of p53.
To gain more mechanistic insights we evaluated dif-
ferent autophagy signalling molecules. The mammalian
target of rapamycin (mTOR), when is activated by protein
kinase B (PKB/Akt), drives the phosphorylation of
autophagy proteins including S61–4. The 5′-AMP-acti-
vated protein kinase (AMPK) can also impact on autop-
hagy1–4,35. Within the temporal window of climacostol
effects on autophagosomes, climacostol (30 μg/ml) trig-
gered an early (3–6 h) decrease of Akt and S6 phos-
phorylation in B16-F10 cells which persisted over-time
(Fig. 7a). In contrast, activated AMPKα substantially
peaked at 6 h of treatment. Similar results were obtained
in vivo, analysing melanoma allografts intra-tumour
injected with 100 µl climacostol at 600 μg/ml or vehicle
(control) every 3–4 days. The activity of S6 was lower in
climacostol-injected tumours (at day 16 of treatment)
while phosphorylated AMPKα increased (Fig. 7b), thus
conﬁrming that climacostol inhibits and stimulates
mTOR and AMPK pathways, respectively. B16-F10 cells
were then transfected for 48 h with an AMPKα-speciﬁc or
a non-targeting siRNA, followed by climacostol treatment
(24 h, 30 μg/ml). When the expression of AMPKα halved,
the lipidation of LC3 by climacostol increased while p62
levels were signiﬁcantly reduced (Fig. 7c), indicating the
accumulation of autophagosomes via AMPK activation.
We next measured the phosphorylation of Akt/S6/
AMPK after p53 silencing in cultured B16-F10 cells
treated with 30 μg/ml climacostol for 6 h. In these con-
ditions, the climacostol-induced up-regulation of p53 was
abolished (Supplementary Fig. 2c). Notably, the decrease
of Akt and S6 activity induced by climacostol was
unchanged in non-targeting siRNA and p53 siRNA cells
(Fig. 7d). On the contrary, the ablation of p53 signiﬁcantly
inhibited climacostol activation of AMPKα, that therefore
is partially p53-dependent. AMPK regulates p53 acetyla-
tion and phosphorylation in cancers36. In B16 cells, the
activation of AMPKα by the toxic natural compound
vincristine is involved in p53 activation37. We found this
not to be a key mechanism in our system since B16-F10
cell transfection with an AMPKα-speciﬁc siRNA did not
affect p53 levels induced by climacostol (30 μg/ml)
(Fig. 7e).
Autophagy disruption and apoptotic cell death
The autophagy modulation in context with apoptosis
was assessed in vivo. Climacostol at 2 and 4mg/kg or
vehicle (control) was injected intraperitoneally in mice
every 3–4 days for 4 weeks, in line with the dosage used in
the intra-tumour treatments. No animal died in the
experimental or the control group; all mice appeared
healthy and clinically normal, with no behavioural chan-
ges, suggesting the absence of systemic toxicity. The
weight of climacostol-administered animals tended to
increase, which was consistent with that of the control
(Table 1). GFP-expressing B16-F10 cells (B16-GFP) were
injected into the tail vein of syngeneic mice the week
before climacostol intraperitoneal treatment (4 mg/kg
every 3–4 days for 2 weeks) and diaphragm was analysed
by ﬂuorescence microscopy 3 weeks after transplantation.
Tumour foci (Supplementary Fig. 2d), i.e., GFP and
melan-A-positive cells, were clearly observed in dia-
phgram tissue (Fig. 8a). Melanoma cells expressed robust
LC3 puncta and cleaved-caspase 3 staining (Fig. 8a) while
these markers were almost undetectable in muscular
(laminin-positive) cells (Fig. 8b).
Autophagy and apoptosis cross-talk functions to
maintain cellular homeostasis and respond to stress38. To
test whether autophagy has a key role regulating cell fate
in our system, we measured the cytotoxic effect of cli-
macostol by exclusion dye staining with trypan blue in
B16-F10 cells transfected with an AMPKα-speciﬁc or a
non-targeting siRNA. As shown in Fig. 8c and
(see ﬁgure on previous page)
Fig. 2 Climacostol impairs autophagy in melanoma cells. B16-F10 cells were cultured in the presence of 30 μg/ml climacostol (CLIMA) or control
vehicle (CTRL) for 24 h. a, c Immunoﬂuorescence imaging of LC3 and p62. Phalloidin and DAPI were used for cytoskeleton and nuclei detection,
respectively. Scale bar: 50 μm. Inserts represent enlarged image details. Right panels: quantitative analysis of LC3 and p62 immunoﬂuorescence
( > 30 cells per experimental condition). Results are expressed as fold change of CTRL. Images and data are representative of 6 independent
experiments. b, d Western blotting images of LC3 and p62 expression. LDH was used as internal standard. Right panels: densitometric analysis of
LC3-II and p62 relative to their respective standard. Results are expressed as fold change of CTRL. Images and data are representive of 11–15
independent experiments. **p < 0.005 and ***p < 0.0001 relative to CTRL
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Supplementary Fig. 2e, cell viability of AMPKα siRNA
cells remained high. Climacostol (24 h, 30 μg/ml)
displayed a similar high toxicity both in the presence
of AMPKα or when its expression was knocked-down.
A similar result was observed after compound C
treatment (Supplementary Fig. 2f), a well-known inhibitor
of AMPK.
Finally, B16-F10 cells were treated with climacostol (24 h,
30 μg/ml) both in the absence and presence of the pan-
caspase inhibitor Z-VAD-(OMe)-FMK at 100 μM. The
Fig. 3 Climacostol impairs autophagic ﬂux. a, b Western blotting images of LC3 and p62 expression in B16-F10 cells cultured with 30 μg/ml
climacostol (CLIMA) or control vehicle (CTRL) for 24 h, both in the absence and presence of chloroquine (CQ; 10 μM, 6 h). LDH was used as internal
standard. Lower panels: densitometric analysis of LC3-II and p62 relative to their respective standard. Results are expressed as fold change of CTRL. Images
and data are representative of 3–5 independent experiments. *p < 0.05, **p < 0.005 and ***p < 0.0001 relative to CTRL. c Electron microscopy images
presenting ultrastructure of B16-F10 cells cultured with 30 μg/ml CLIMA or CTRL for 6 h. The panels 1–3 depict representative control cells at increasing
magniﬁcations: (1) whole cells; (2) an early or initial autophagic vacuole (Avi), containing morphologically intact ribosomes. The electron-lucent cleft
between the two limiting membranes is visible. A dense lysosome (Ly) is also found in contact with the outer limiting membrane of the autophagosome
and a normal mitochondria (mi); (3) a late or degradative autophagic vacuole (Avd) containing partially degraded cytoplasmic material. The panels 4–7
depict representative climacostol-treated cells at increasing magniﬁcations: (4) whole cells showing abundant black melanosomes; (5) note the presence
of numerous autophagosome-like compartments in the cytoplasm; (6) higher magniﬁcation of melanosomes and (7) mitochondria with swollen cristae.
Scale bars: 1 and 4: 2 μm; 2 and 3: 200 nm; 5, 6 and 7: 500 nm. Images are representative of 3 independent experiments
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activation of caspase 3 induced by climacostol was reduced
by Z-VAD-(OMe)-FMK (Fig. 8d). In contrast, caspase
inhibition did not affect the accumulation of LC3-II and p62
(Fig. 8e) obtained after climacostol treatment thus clear-
ly indicating that the activation of caspases is not
associated with climacostol disruption of autophagic ﬂux.
Z-VAD-(OMe)-FMK administration did not rescue
climacostol-induced reduction of MTT absorbance (Fig. 8f)
thereby suggesting that climacostol effects on cell viability
are not necessarily mediated by caspase-dependent
mechanisms.
Discussion
The cellular homeostatic process autophagy occurs at a
basal level in all eukaryotic cells and may support cell
survival or activate death pathways10,11. Many of the
core autophagy genes found in humans are expressed in
ciliated protozoa39. Alveolata (comprising single-celled
ciliates, dinoﬂagellates and Apicomplexa) share with
Opisthokonta (including Fungi and Animalia) a last
common ancestor about 1.5 billion years ago. Notwith-
standing the diversity and the evolutionary interval that
separate these organisms, ciliates provide versatile
Fig. 4 Climacostol impairs autophagic ﬂux. B16-F10 cells were cultured with 30 μg/ml climacostol (CLIMA) or control vehicle (CTRL) for increasing
times. Chloroquine (CQ; 10 μM, 6 h) was also used. a Confocal ﬂuorescence imaging of cells transiently transfected with mRFP-GFP-LC3 plasmid. This
tandem ﬂuorescent-tagged LC3 reporter results in both green (GFP) and red (RFP) ﬂuorescence: autophagosomes appear yellow (with green and red
ﬂuorescence) and autolysosomes as only red vacuoles. Scale bar: 30 μm. Inserts represent enlarged image details highlighting the presence of red
(arrows) and yellow puncta. b The number of autophagosomes and the number of autolysosomes in the merged images were counted and the total
number of puncta per cell was calculated as percentage (>30 cells per experimental condition). *p < 0.05 relative to CTRL. c Western blotting images
of LC3 and p62 expression. LDH was used as internal standard. Images and data are representative of 3 independent experiments
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molecular tools to determine autophagic pathway in
mammals6. They synthesise a great variety of chemicals
with biotech potential18,40. Our present ﬁndings show that
climacostol, a pro-apoptotic natural compound produced
by the ciliated protozoan Climacostomum virens, potently
impairs autophagy. Climacostol, which has a chemical
structure distinct from the current blockers of autophagic
ﬂux8,15, exerts a sustained accumulation of autophago-
somes in tumour cells as the result of dysfunctional
autophagic degradation. The analysis of B16-F10 allo-
grafts revealed a disruption of autophagy when melano-
mas were treated with intra-tumoural injections of
climacostol. In addition, non-toxic doses of intraper-
itoneally administered climacostol reached diaphragm
muscle selectively targeting transplanted melanoma cells,
which thus showed impaired autophagy and were com-
mitted to die by apoptosis. In some cases climacostol
toxicity was reported to be higher against tumour than
non-tumour cells18,21,23 and not only cell death/apoptosis
but also the impairment of autophagy was induced by
climacostol in multiple cancer cell lines, i.e., human
melanomas and murine/human glial tumour cells.
Moreover, local delivery of climacostol inhibited mela-
noma growth thus inducing apoptosis and a signiﬁcant
improvement of animal survival18,23. These data indicate
climacostol as a highly effective compound against a
wide range of cancers, including those affecting humans.
Many natural compounds exert pro- and anti-autophagic
activity and thus may contribute to treatments of diverse
human diseases32,41. Autophagy inhibition is a promising
strategy and different agents disrupting autophagy are
being evaluated in clinical trials for cancer treatment14,15.
This study suggests that screening autophagy regulators
from natural compounds might be an efﬁcient metho-
dology to identify novel autophagy inhibitors and lead
compounds for cancer therapy.
Autophagy and apoptosis share key regulatory proteins,
suggesting that the pathways regulating them are con-
nected38,42. Since climacostol participates in the impair-
ment of autophagy while inducing apoptosis, its action
may be situated at the molecular crossroads regulating
both autophagy and apoptosis. Our present data provide
molecular ground and conﬁrm this hypothesis. Firstly we
demonstrated further that climacostol elicits apoptosis via
p5318,23. Cimacostol activates p53, likely as a result of
DNA damage, and its signalling, i.e., Noxa and
PUMA18,23, inducing a quick up-regulation of p53 in the
nuclei. This is not a change in gene transcription-
mechanism but occur through effects on p53 stability at
translational level25,26, as for instance the phosphorylation
at Ser15 site. p53 is both a promoter and a suppressor of
autophagy and these effects establish a p53-dependent cell
fate25,28. We unravelled a double-edged role played by
climacostol in either promoting autophagy, independently
on p53 levels, or suppressing autophagosome turnover via
the up-regulation of p53. In this way, i.e., coordinately
inducing autophagosome accumulation and inhibiting the
Fig. 5 Climacostol effects in multiple tumour cell lines. MTT assay
assessing the viability of A375 (a), SK-MEL-5 (b), GL261 (c), and U87MG
(d) cells treated with increasing concentrations of climacostol for 24 h.
Data are expressed by setting the absorbance of the reduced MTT in
the absence of climacostol as 100%. The data points are representative
of 8 independent experiments. Western blotting images of cleaved-
caspase 3, LC3 and p62 expression in A375 (e), SK-MEL-5 (f), GL261 (g),
and U87MG (h) cells cultured in the presence of 30 μg/ml climacostol
(CLIMA) or control vehicle (CTRL) for 24. LDH was used as internal
standard. Images are representive of 3 independent experiments
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autophagic ﬂux, more autophagic vacuoles may be accu-
mulated in tumour cells. The natural compound baﬁlo-
mycin A1 activates early stage of autophagy by
downregulating mTOR pathway, and inhibits later stages
of autophagy in hepatocellular carcinoma involving
PUMA43. In addition, tetrandrine, which blocks autop-
hagic ﬂux and induces apoptosis in cancer cells, has been
shown to induce a signiﬁcant phosphorylation of
AMPK33. In this respect, we provide evidence that the
activation of autophagy by climacostol is likely due to an
inhibition of mTOR signalling unrelated to p53; p53, via
AMPKα activation, is nevertheless involved in the
climacostol-induced impairment of autophagic process as
AMPKα phosphorylation is under its control and the
knock-down of AMPKα inhibited autophagosomes
accumulation by climacostol. Accordingly, the activation
of p53 increased the phosphorylation of AMPK and
inhibited mTOR in cancer cells in which the completion
of autophagy was inhibited44. In melanoma the activation
of AMPK may induce accumulation of autophagosomes
that are unable to be degraded when autophagosome
clearance is inhibited45. Also, pro-inﬂammatory cytokines
inhibit mTOR in β-cells, stimulate the AMPK axis and
block autophagic ﬂux46.
Autophagy may be either protective or toxic10–12 and
AMPK may be connected with apoptosis regulation47. In
melanoma the block of autophagy may aggravate or
induce cell apoptosis45,48–54, due to excessive accumula-
tion of autophagic vacuoles containing deleterious unde-
graded material. Climacostol is an efﬁcient agent acting
fast (between 3 h and 6 h) on autophagic ﬂux resulting in
autophagosome accumulation in the cytosol. Although
dysfunctional autophagy in climacostol-treated cells
occurs prior to detectable apoptosis23, the possibility that
climacostol-induced cell death is downstream autophagy-
related events is not supported by our data. The toxicity of
climacostol against melanoma cells was not affected by
the inhibition of AMPKα, thus the pro-apoptotic function
of climacostol could not be attributed to the block of
autophagosome turnover. Notably, climacostol disruption
of autophagic ﬂux is not associated with the activation of
caspases and climacostol is also able to inhibit tumour cell
viability without the involvement of caspases. These data
indicate that climacostol effects on autophagy and apop-
tosis are two separate events, although both reﬂecting the
upstream activation of p53. Noteworthy, they may act
independently and in a redundant manner on life/death
decisions of the cell. These observations provide a plat-
form for future studies to explore the dual targeting of
autophagy and apoptosis with cytotoxic agents acting on
p53 for the killing of tumours that frequently develop
chemoresistance due to protective autophagy14,15.
In essence, our study shows that climacostol impairs
autophagy in tumours and suggests that the clinical
potential of climacostol should be investigated further.
We also generated valuable mechanistic insights identi-
fying the p53-dependent increase of AMPK activity as the
major responsible of autophagy disruption, although the
mTOR pathway unrelated to p53-AMPK axis also plays a
role. The up-regulation of p53 system is at the molecular
crossroad regulating both the anti-autophagic action of
climacostol and its role in the induction of apoptosis. In
agreement with the promising paradigm of dual targeting
of autophagy and apoptosis, different natural compounds
have been shown to display anti-autophagic ﬂux and pro-
apoptotic effects in cancers33,43,53,55–58. Our ﬁndings
suggest the efﬁcacy of ciliate bioactive molecules, which
have several intrinsic properties18,40,59,60, favouring their
consideration in drug discovery and development.
Materials and methods
Climacostol
Chemically synthesised climacostol (C15H22O2, alkenyl
resorcinol) was obtained as previously described22. The
conﬁguration of the double bond was assigned as a (Z)-
based. Structure-activity studies have indicated that the
C2–C3 unsaturation in the side chain plays a key role for
the biological activity18,22,23,61. The (Z)-diastereomer is
the active organic molecule, while the (E)-diastereomer is
less active. The NMR spectroscopy of the climacostol
obtained by our procedure allowed to determine that the
content of (Z)-diastereomer was major than 99%, without
contamination with the undesired (E)-diastereomer.
Given that in the mixture of the two diastereomers the
separation of the (Z)-diastereomer from its (E)-conﬁg-
uration was not possible through the common methods
(see ﬁgure on previous page)
Fig. 6 p53 is involved in the climacostol regulation of autophagy. a Western blotting images of cleaved-caspase 3 expression in B16-F10 cells
transfected for 48 h with a p53-speciﬁc (p53 siRNA) or a non-targeting siRNA (nt siRNA), followed by vehicle or climacostol (CLIMA) treatment (24 h,
30 μg/ml). Vinculin was used as internal standard. b–d B16-F10 cells were cultured with 30 μg/ml CLIMA or control vehicle (CTRL) for increasing times.
b mRNA levels of p53 gene, as measured by real-time PCR. Results are expressed as fold change of control (dashed line), set as 1. c Western blotting
images of p53 expression. LDH was used as internal standard. d Confocal immunoﬂuorescence imaging of total p53 and p53 phosphorylated at
Ser15 site (p-p53Ser15). Scale bar: 10 μm. DAPI was used for nuclei detection. e Western blotting images of LC3 and p62 expression in B16-F10 cells
transfected for 48 h with a p53-speciﬁc (p53 siRNA) or a non-targeting siRNA (nt siRNA), followed by vehicle or CLIMA treatment (24 h, 30 μg/ml). LDH
was used as internal standard. Right panels: densitometric analysis of LC3-II and p62 relative to their respective standard. Results are expressed as fold
change of nt siRNA. ***p < 0.0001 relative to nt siRNA, #p < 0.05 relative to p53 siRNA, §p < 0.05 relative to nt siRNA+ CLIMA. Images and data are
representative of 3 independent experiments
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of separation, the natural toxin puriﬁed from cultures
of Climacostomum virens was less active than synthetic
climacostol. The latter one was then dissolved in absolute
ethanol at 10 mg/ml stock, and stored in the dark at
−20 °C until use. The stock solution of climacostol was
diluted in phosphate buffered saline (PBS) (Euroclone,
Pero, Italy) or in culture medium for in vivo injections
and in vitro experiments, respectively. Where not
indicated, the other reagents were purchased from Sigma-
Aldrich (Saint Louis, MO, USA).
Animals and cell cultures
Female C57BL/6 mice (8–12 weeks old) were purchased
from Charles River Laboratories (Calco, Italy), housed in
a regulated environment (23 ± 1 °C, 50 ± 5% humidity)
with a 12 h light/dark cycle (lights on at 08.00 a.m.),
and provided with food and water ad libitum. All studies
were conducted in accordance with the Italian law on
animal care N° 116/1992 and the European Communities
Council Directive EEC/609/86. All efforts were made
to reduce both animal suffering and the number of ani-
mals used.
Murine melanoma B16-F10, murine glioma GL261,
human glioblastoma U87MG23,54,62–64, human melanoma
A375 and SK-MEL-5 (obtained by the American
Type Culture Collection) cell lines were cultured in
Iscove’s supplemented with 10% heat-inactivated foetal
bovine serum, glutamine (2 mM), penicillin/streptavidin
(100 U/ml), 1% Hepes 1M (Euroclone), pH 7.4. Cells were
grown at 37 °C in a humidiﬁed atmosphere containing
5% CO2 (logarithmic growth phase, routine passages
every 3 days). To create B16-GFP cells, B16-F10 cells
were transfected with lentivirus pLVX-Puro (Takara Bio
USA, Mountain View, CA, USA) encoding for EGFP,
produced upon transfection of HEK-293T packaging cells
with the lentiviral vector. After two cycles of infection
cells were selected with puromycine (1 ug/ml) for 2 weeks
in order to obtain a stable GFP-expressing cell line.
RNA interference
Gene silencing of p53 and AMPKα in B16-F10 cells was
performed as previously published23,37. Brieﬂy, according
to the manufacturer’s protocol, iBONI siRNA Pool
(Riboxx, Radebeul, Germany) targeting mouse p53 (trp53)
and AMPKα1/2 (Santa Cruz Biotechnology, Dallas,TX,
USA) targeting mouse AMPKα (prkaa1 and prkaa2) were
mixed to Lipofectamine RNAiMax transfection reagent
(Life Technologies, Monza, Italy). iBONI siRNA Pool
negative control (Riboxx) and control siRNA-A (Santa
Cruz Biotechnology) (non-targeting siRNAs) were also
used. The mix was added to cultured B16-F10 cells at a
siRNA concentration of 10–50 nM for 48 h.
Animal handling and allograft tumour models
Using published protocols18,23,54,62–65, mice (weighing
18–21 g) received subcutaneous injections of 5 × 104 cells
B16-F10 in the lower-right ﬂank. When the syngeneic
implantation was established (usually 10 days after
tumour cells inoculation) and the tumour was palpable
(volume range between 15–30mm3), mice were randomly
(see ﬁgure on previous page)
Fig. 7 Autophagy signalling molecules involved in the climacostol regulation of autophagy. a B16-F10 cells were cultured with 30 μg/ml
climacostol (CLIMA) or control vehicle (CTRL) for increasing times. Western blotting images of phosphorylated Akt, S6 and AMPKα. The total Akt, S6
and AMPK were used as internal standard. Images are representative of 6 independent experiments. bWestern blotting images of phosphorylated S6
and AMPK in subcutaneous B16-F10 melanoma allografts excised from mice at day 16 of treatment (from day 0 - every 3–4 days) with 100 µl CLIMA
(600 μg/ml) or CTRL. The total S6 and AMPK were used as internal standard. Images represent the results obtained from 6 animals per experimental
group. cWestern blotting images of AMPKα, LC3 and p62 expression in B16-F10 cells transfected for 48 h with an AMPKα-speciﬁc (AMPKα siRNA) or a
non-targeting siRNA (nt siRNA), followed by CLIMA treatment (24 h, 30 μg/ml). LDH was used as internal standard. Right panels: densitometric analysis
of AMPKα, LC3-II and p62 relative to their respective standard. Results are expressed as fold change of nt siRNA+ CLIMA. Images and data are
representative of 3 independent experiments. *p < 0.05 and **p < 0.005 relative to nt siRNA+ CLIMA. d Western blotting images of phosphorylated
Akt, S6 and AMPKα in B16-F10 cell transfected for 48 h with a p53-speciﬁc (p53 siRNA) or a non-targeting siRNA (nt siRNA), followed by vehicle or
CLIMA treatment (6 h, 30 μg/ml). The total Akt, S6 and AMPKα were used as internal standard. Right panels: densitometric analysis of phosphorylated
proteins relative to their respective standard. Results are expressed as fold change of nt siRNA. Images and data are representative of 3 independent
experiments. **p < 0.005 and ***p < 0.0001 relative to nt siRNA; #p < 0.05, ##p < 0.005 and ###p < 0.0001 relative to p53 siRNA, §p < 0.05 relative to nt
siRNA+ CLIMA. eWestern blotting images of AMPKα and p53 expression in B16-F10 cells transfected for 48 h with an AMPKα-speciﬁc (AMPKα siRNA)
or a non-targeting siRNA (nt siRNA), followed by vehicle or CLIMA treatment (24 h, 30 μg/ml). LDH was used as internal standard. Images are
representative of 3 independent experiments
Table 1 Body weight data
Week CTRL CLIMA
2mg/kg 4mg/kg
0 20.80 ± 0.28 20.78 ± 0.08 20.72 ± 0.23
1 22.27 ± 0.44 21.75 ± 0.52 21.39 ± 0.35
2 23.34 ± 0.58 22.79 ± 0.13 22.73 ± 0.58
3 24.29 ± 0.58 24.09 ± 0.54 24.36 ± 0.23
4 25.42 ± 0.57 25.08 ± 0.41 25.47 ± 0.48
The data points are expressed in grams and have been obtained from 3 animals
per experimental group
CTRL control (vehicle), CLIMA climacostol
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assigned to one of the two experimental groups. In par-
ticular, transplanted mice received 100 μl intra-tumour
injections of vehicle or climacostol (600 μg/ml, equivalent
to ca. a concentration of 3 mg/kg dose) every 3–4 days. At
day 16, mice were sacriﬁced, tumours removed and pro-
cessed. In testing the toxicity of intraperitoneal injections
of climacostol, mice were administered with dissolved
drug (at 2 and 4mg/kg) or vehicle every 3–4 days for
4 weeks. In another set of experiments, mice received 1 ×
105 B16-GFP cells into the tail vein62. The week after,
climacostol was intraperitoneally injected every 3–4 days
at 4 mg/kg. Two weeks after climacostol treatment, mice
were sacriﬁced and the diaphragm skeletal muscle tissue
removed.
Real-time PCR
The analysis of mRNA expression was performed as
previously described18,23,62,66,67. Brieﬂy, total RNA from
in vivo resected B16-F10 tumours and in vitro B16-F10
cells was extracted with the High Pure RNA Tissue Kit
and the High Pure RNA Isolation Kit, respectively (Roche
Applied Science, Mannheim, Germany), according to the
manufacturer’s protocol. First-strand cDNA was gener-
ated from 1 μg of total RNA using iScript Reverse Tran-
scription Supermix (Bio-Rad, Hercules, CA, USA). A set
of primer pairs (Euroﬁns Genomics, Milano, Italy) was
designed to hybridize to unique regions of the appropriate
gene sequence (Supplementary Table 1). PCR was per-
formed using SsoAdvanced Universal SYBR Green
Supermix and the CFX96 Touch Real-Time PCR Detec-
tion System (Bio-Rad). The fold change was determined
relative to the selected control sample after normalising to
Rpl32 (internal standard) by the formula 2-ΔΔCT.
Fluorescence microscopy
As previously published18,23,54,68 in vivo resected B16-
F10 tumours were immersion-ﬁxed in 4%
paraformaldehyde in 0.1M phosphate buffer (PB), pH 7.4,
for 3 h. The ﬁxed tissue was transferred to 25% sucrose in
PB. Tumour sections were cut at 10 μm with a cryostat,
mounted onto positively charged slides and stored at −20
°C. Dissected diaphragm tissues69,70 were rapidly frozen
and then cut at 10 μm with a cryostat, mounted onto
positively charged slides and stored at −20 °C until use.
Slides were then immersion-ﬁxed in 4% paraformalde-
hyde in PB, pH 7.4, for 10 min. Sections were treated for
30min at room temperature with 5% bovine serum
albumin and 10% of normal goat serum (Life Technolo-
gies) in PB containing 0.5% Triton X-100. Overnight
incubation was performed with one of the following rabbit
primary antibodies: anti-LC3, anti-p62/SQSTM1 and
anti-laminin A (Sigma-Aldrich), anti-melan-A (GeneTex,
Irvine, CA, USA), anti-cleaved-caspase 3 (Cell Signaling
Technology, Danvers, MA, USA)71,72 in PB containing
0.5% Triton X-100. For ﬂuorescence detection, sections
were stained with the appropriate Alexa Fluor secondary
antibody (Life Technologies) in PB containing 0.5% Triton
X-100 for 1.5 h and cover-slipped with Fluoroshield
Mounting Medium containing DAPI (nuclei detection)
(Abcam, Cambridge, UK). Incubation in secondary anti-
body alone was performed as a negative control. Images of
resected tumours were acquired by a Zeiss Axioskop 2
plus microscope equipped with the Axiocam MRC pho-
tocamera and the Axiovision software (Carl Zeiss, Ober-
kochen, Germany). Images of diaphragm tissue were
acquired by a Zeiss LSM 710 inverted confocal
microscope.
Using published protocols23,54,62, in vitro B16-F10 cells
cultured in 120-mm coverslips were ﬁxed in 4% paraf-
ormaldehyde in 0.1M PB, pH 7.4, for 10 min and over-
night stained with rabbit anti-LC3, anti-p62/SQSTM1
and anti-phospho-p53 (Ser15), and mouse anti-p53 (Cell
Signaling Technology) primary antibodies. Cells were
also stained with the appropriate Alexa Fluor secondary
(see ﬁgure on previous page)
Fig. 8 Autophagy/cell death events induced by climacostol. a, b GFP-expressing B16-F10 cells were injected into the tail vein of syngeneic mice
the week before climacostol intraperitoneal treatment (4 mg/kg every 3–4 days for 2 weeks). Diaphragm, a skeletal muscle separating the thoracic/
peritoneal cavities, was analysed by confocal microscopy 3 weeks after transplantation. a Confocal immunoﬂuorescence imaging of melan-A, LC3
and cleaved-caspase 3 in tumour foci observed in the sections of diaphgram tissue. The signal of GFP (tumour cells) and DAPI (nuclei) was also
detected. b Confocal immunoﬂuorescence imaging of laminin, LC3 and cleaved-caspase 3 in diaphgram muscle. DAPI was used for nuclei detection.
Scale bar: 50 μm. Images represent the results obtained from 5 animals. c Exclusion dye staining with trypan blue in B16-F10 cells (>5 × 105 cells per
experimental condition) transfected for 48 h with an AMPKα-speciﬁc (AMPKα siRNA) or a non-targeting siRNA (nt siRNA), followed by vehicle or
climacostol (CLIMA) treatment (24 h, 30 μg/ml). Data are expressed by setting the number of living cells in control samples as 100%. Data are
representative of 3 independent experiments. ***p < 0.0001 relative to nt siRNA; ###p < 0.0001 relative to AMPKα siRNA. d - f B16-F10 cells were
cultured with 30 μg/ml CLIMA or control vehicle (CTRL) for 24 h, both in the absence and presence of the pan-caspase inhibitor Z-VAD-(OMe)-FMK
(Z-VAD; 100 μM). d Western blotting images of cleaved-caspase 3 expression. Vinculin was used as internal standard. Right panel: densitometric
analysis of cleaved-caspase 3 relative to the standard. Results are expressed as fold change of CLIMA. Images and data are representative of 3
independent experiments. **p < 0.005 relative to CLIMA.e Western blotting images of LC3 and p62 expression. LDH was used as internal standard.
Right panels: densitometric analysis of LC3-II and p62 relative to their respective standard. Results are expressed as fold change of CTRL. Images and
data are representative of 3 independent experiments. **p < 0.005 and ***p < 0.0001 relative to CTRL; ##p < 0.005 and ###p < 0.0001 relative to Z-VAD.
f MTT assay assessing cell viability. Data are expressed by setting the absorbance of the reduced MTT in control samples as 100%. Data are
representative of 8 independent experiments. ***p < 0.0001 relative to CTRL; ###p < 0.0001 relative to Z-VAD
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antibodies in PB containing 0.5% Triton X-100 for 1 h
and cover-slipped in a ProLong Gold Antifade Mountant
(Life Technologies), stained with ﬂuorescein phalloidin
(cytoskeleton detection) (Life Technologies) and DAPI
(Sigma-Aldrich). Slides were analysed using a DMI4000 B
automated inverted microscope equipped with a DCF310
digital camera (Leica Microsystems, Wetzlar, Germany).
Confocal imaging was performed with a Leica TCS SP5
AOBS microscope system. Image acquisitions were con-
trolled by the Leica LAS AF software.
To perform quantitative analysis for LC3 and p62
immunostaining72–74, images were converted to grayscale
and normalised to background using Adobe Photoshop
software (Adobe Systems, Mountain View, CA, USA).
Mean gray levels were then measured in the selected
tumour area or cells.
Western blotting
Using published protocols18,23,54,62,75,76, in vivo resected
B16-F10 tumours and human or murine cancer cell lines
were homogenised in RIPA lysis buffer, supplemented
with a cocktail of protease and phosphatase inhibitors
(cOmplete and PhosSTOP; Roche Diagnostics, Milano,
Italy). Equal amounts of proteins were separated by
4–20% SDS-polyacrylamide gel electrophoresis (Criterion
TGX Stain-free precast gels and Criterion Cell system;
Bio-Rad) and transferred onto nitrocellulose membrane
using a Bio-Rad Trans-Blot Turbo System. When indi-
cated, the membranes were probed using the rabbit anti-
LC3, anti-p62/SQSTM1, anti-cleaved-caspase 3, anti-
phospho-Akt (Ser473), anti-phospho-S6 (Ser240/244),
anti-phospho-AMPKα (Thr172) and mouse anti-p53 (Cell
Signaling Technology)71,72 primary antibodies. After the
incubation with the appropriate horseradish-peroxidase-
conjugated secondary antibody (Cell Signaling Technol-
ogy), bands were visualised using the Clarity Western ECL
substrate with a ChemiDoc MP imaging system (Bio-Rad).
To monitor for potential artefacts in loading and transfer
among samples in different lanes, the blots were routinely
treated with the Restore Western Blot Stripping Buffer
(ThermoFisher Scientiﬁc, Waltham, MA, USA) and re-
probed with the mouse anti-vinculin (Sigma-Aldrich) or
goat anti-LDH-A (Santa Cruz Biotechnology). Primary
antibodies, i.e., rabbit anti-Akt and anti-AMPKα, and
mouse anti-S6 (Cell Signaling Technology), that recognize
the protein independently of its phosphorylation state,
were also used in re-probing experiment for normal-
isation purposes. When appropriated, bands were quan-
tiﬁed for densitometry using the Bio-Rad Image Lab
software.
Transmission electron microscopy
The collected B16-F10 cells were stored overnight at
4 °C in a ﬁxative solution containing 2.5% (v/v)
glutaraldehyde and 2% (v/v) paraformaldehyde in 0.1M
cacodylate buffer, pH 7.2. Fixed cells were washed in
cacodylate buffer and post-ﬁxed with 2% (v/v) osmium
tetroxide in 0,1M cacodylate buffer, pH 7.2 for 2 h at 4 °C.
Samples were washed in the same buffer and dehydrated
through an ascending series of ethanol and embedded
in LRWhite resin (Electron Microscopy Science, PA,
USA). For ultrastructural observations at least 20 ultra-
thin sections (60–90 nm) were obtained using a Reichert
Ultracut ultramicrotome equipped with a diamond
knife (Leica Microsystems). Ultra-thin sections were
collected on copper grids, stained with uranyl acetate
and lead citrate, and observed with a 1200 EXII electron
microscope (Jeol, Tokyo, Japan). Micrographs were cap-
tured by the SIS VELETA CCD camera equipped with
iTEM software (Olympus, Tokyo, Japan).
MTT and Trypan blue viability assay
Cell viability on human or murine cancer cell lines
was determined by MTT assay using published proto-
cols59,60,62,67,77–79. MTT absorbance was quantiﬁed spec-
trophotometrically using a Glomax Multi Detection
System microplate reader (Promega, Milano, Italy). B16-
F10 cells were also stained with trypan blue (Bio-Rad) and
the amount of living cells was determined using a Bio-Rad
TC10 Automat Cell Counter. Cells were visualised using
a Leica DMI4000 B automated inverted microscope
equipped with a DCF310 digital camera.
mRFP-GFP-LC3 assay
B16-F10 cells were plated on 14mm coverslips coated
with poly-D-lysine and then cultured for 24 h. Cells were
then transiently transfected with tandem ﬂuorescent
mRFP-GFP-LC3 plasmid80, kindly provided by Dr. Pura
Muñoz-Cánoves (Pompeu Fabra University, Barcelona,
Spain), using Lipofectamine LTX and Plus Reagent
(Life Technologies). Three hours following transfection
at 37 °C, two-thirds of the media is replenished with fresh
media. After drug treatments, cells were washed once in
PBS and ﬁxed with 4% paraformaldehyde (in PBS) for 15
min at room temperature. After washing, coverslips were
mounted on glass slides with ProLong Gold Antifade
Mountant with DAPI and analysed using a Carl-Zeiss
LSM 710 inverted confocal microscope. The number of
autophagosomes (number of yellow puncta per cell) and
autolysosomes (number of red puncta per cell) was
quantiﬁcated per cell, and at least 100 cells for each
experiment were included.
Statistics
Statistical signiﬁcance of raw data between the groups
in each experiment was evaluated using unpaired Stu-
dent’s t test (single comparisons) or one-way ANOVA
followed by the Newman-Keuls post-test (multiple
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comparisons). EC50 (the concentration producing half the
maximum effect) and Emax concentration (producing the
maximum effect) were determined by non-linear regres-
sion curve analysis of the concentration-effect responses.
Potency values among concentration-response curves
were compared with the F-test. Data belonging from
different experiments were represented and averaged in
the same graph. The GraphPad Prism software package
(GraphPad Software, San Diego, CA, USA) was used. The
results were expressed as means ± SEM of the indicated n
values.
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